קייליקס ישראל - עברית - Ministry of Health

קייליקס

j-c health care ltd - doxorubicin hydrochloride - liposome for infusion - doxorubicin hydrochloride 2.0 mg/ml - doxorubicin - doxorubicin - first or second line therapy of aids related kaposis sarcoma in patients with low cd 4 counts and extensive mucocutaneous or visceral disease the treatment of patients with metastatic carcinoma of the ovary who are refractory to both paclitaxel and platinium-based chemotherapy regimens and who may also be refractory to topotecan. refractory is defined as a patient having progressive disease while on treatment or within 6 months of completing treatmnt. as monotherapy for patients with metastatic breast cancer where there is an increased cardiac risk. in combination with bortezomib for the treatment of progressive multiplemyeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant.

אמווסי ישראל - עברית - Ministry of Health

אמווסי

amgen europe b.v. - bevacizumab - תרכיז להכנת תמיסה לאינפוזיה - bevacizumab 25 mg / 1 ml - bevacizumab

מיוסט 50 מג ישראל - עברית - Ministry of Health

מיוסט 50 מג

medison pharma ltd - doxorubicin hydrochloride - אבקה, מפזר וממס להכנת תרכיז לפיזור באינפוזיה - doxorubicin hydrochloride 50 mg vials - doxorubicin - doxorubicin - myocet, in combination with cyclophosphamide, is indicated for the first line treatment of metastatic breast cancer in women.

קייליקס ליפוזומל ישראל - עברית - Ministry of Health

קייליקס ליפוזומל

j-c health care ltd - doxorubicin hydrochloride - doxorubicin hydrochloride 2.0 mg/ml - doxorubicin

קייליקס ליפוזומל ישראל - עברית - Ministry of Health

קייליקס ליפוזומל

baxter healthcare distribution ltd., israel - doxorubicin hydrochloride - doxorubicin hydrochloride 2.0 mg/ml - doxorubicin

סירמזה 10 מגמל ישראל - עברית - Ministry of Health

סירמזה 10 מגמל

eli lilly israel ltd, israel - ramucirumab - תרכיז להכנת תמיסה לאינפוזיה - ramucirumab 10 mg/ml - ramucirumab

גמציטבין " אבווה" 200 מ"ג ישראל - עברית - Ministry of Health

גמציטבין " אבווה" 200 מ"ג

pharmalogic ltd - gemcitabine as hydrochloride 200 mg - lyophilized powder for injection - gemcitabine - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer. gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. breast cancer: gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ovarian cancer: gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.

גמציטבין " אבווה" 200 מ"ג ישראל - עברית - Ministry of Health

גמציטבין " אבווה" 200 מ"ג

pharmalogic ltd - gemcitabine as hydrochloride 200 mg - lyophilized powder for injection - gemcitabine - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer. gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. breast cancer: gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ovarian cancer: gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.

גמציטבין "אבווה " 1 גרם ישראל - עברית - Ministry of Health

גמציטבין "אבווה " 1 גרם

pharmalogic ltd - gemcitabine as hydrochloride 1000 mg - lyophilized powder for injection - gemcitabine - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer. gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. breast cancer: gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ovarian cancer: gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.

גמציטבין "אבווה " 1 גרם ישראל - עברית - Ministry of Health

גמציטבין "אבווה " 1 גרם

pharmalogic ltd - gemcitabine as hydrochloride 1000 mg - lyophilized powder for injection - gemcitabine - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer. gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. breast cancer: gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ovarian cancer: gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.